De novo thrombotic microangiopathy after non-renal solid organ transplantation

Blood Reviews

Volumn 28, Issue 6, 2014, Pages 269-279

  Verbiest, Annelies ^a   Pirenne, Jacques ^a   Dierickx, Daan ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

ADAMTS13; Calcineurin inhibitor; Heart transplantation; Intestinal transplantation; Liver transplantation; Lung transplantation; MTOR inhibitor; Organ transplantation; Plasma exchange; Thrombotic microangiopathy; Von willebrand factor

Indexed keywords

CALCINEURIN INHIBITOR; FOLIC ACID; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANALYTICAL PARAMETERS; CLINICAL FEATURE; COOMBS TEST; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG RECHALLENGE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; EXPERIMENTAL THERAPY; GRAFT RECIPIENT; HEART TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE TRANSPLANTATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PATHOGENESIS; PLASMA TRANSFUSION; PLASMAPHERESIS; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROGNOSIS; REPERFUSION INJURY; REVIEW; RISK FACTOR; SOLID ORGAN TRANSPLANTATION; SURVIVAL RATE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSPLANTATION ASSOCIATED THROMBOTIC MICROANGIOPATHY; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR VON WILLEBRAND FACTOR CLEAVING PROTEINASE RATIO; ADVERSE EFFECTS; PROCEDURES; THROMBOTIC MICROANGIOPATHIES;

HUMANS; ORGAN TRANSPLANTATION; THROMBOTIC MICROANGIOPATHIES;

EID: 84923996371     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2014.09.001     Document Type: Article

References (95)

1. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc NY Pathol Soc 1924, 24:21-24.
2. Ponticelli C., Banfi G. Thrombotic microangiopathy after kidney transplantation. Transpl Int 2006, 19(10):789-794.
3. Ho V.T., Cutler C., Carter S., Martin P., Adams R., Horowitz M., et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005, 11(8):571-575.
4. Ruutu T., Barosi G., Benjamin R.J., Clark R.E., George J.N., Gratwohl A., et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 2007, 92(1):95-100.
5. Kojouri K., George J.N. Thrombotic microangiopathy following allogeneic hematopoietic stem cell transplantation. Curr Opin Oncol 2007, 19(2):148-154.
6. Rock G.A., Shumak K.H., Buskard N.A., Blanchette V.S., Kelton J.G., Nair R.C., et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991, 325:393-397.
7. Michael M., Elliott E.J., Ridley G.F., Hodson E.M., Craig J.C. Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Cochrane Database Syst Rev 2009, 1:CD003595.
8. Galbusera M., Noris M., Remuzzi G. Thrombotic thrombocytopenic purpura - then and now. Semin Thromb Hemost 2006, 32(2):81-89.
9. Sadler J.E. Thrombotic thrombocytopenic purpura: a moving target. ASH education program book 2006, 1:415-420.
10. Besbas N., Karpman D., Landau D., Loirat C., Proesmans W., Remuzzi G., et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 2006, 70(3):423-431.
11. Elliott M., Nichols W. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Mayo Clin Proc 2001, 76(11):1154-1162.
12. Shindoh J., Sugawara Y., Akamatsu N., Kaneko J., Tamatsu S., Yamashiki N., et al. Thrombotic microangiopathy after living-donor liver transplantation. Am J Transplant 2012, 12(3):728-736.
13. Miyata R., Shimazu M., Tanabe M., Kawachi S., Hoshino K., Wakabayashi G., et al. Clinical characteristics of thrombotic microangiopathy following ABO incompatible living donor liver transplantation. Liver Transpl 2007, 13(10):1455-1462.
14. Hachem R.R., Yusen R.D., Chakinala M.M., Aloush A.A., Patterson G.A., Trulock E.P. Thrombotic microangiopathy after lung transplantation. Transplantation 2006, 81(1):57-63.
15. Scully M., Hunt B.J., Benjamin S., Liesner R., Rose P., Peyvandi F., et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012, 158(3):323-335.
16. Lefaucheur C., Nochy D., Amrein C., Chevalier P., Guillemain R., Cherif M., et al. Renal histopathological lesions after lung transplantation in patients with cystic fibrosis. Am J Transplant 2008, 8(9):1901-1910.
17. Turner D., Schreiber R., Grant D., Hebert D., Sherman P.M. Hemolytic uremic syndrome after pediatric liver transplantation. J Pediatr Gastroenterol Nutr 2006, 43(7):109-112.
18. Tamura S., Sugawara Y., Matsui Y., Kishi Y., Akamatsu N., Kaneko J., et al. Thrombotic microangiopathy in living-lonor liver transplantation. Transplantation 2005, 80(2):169-175.
19. Shimazu M., Kitajima M. Living donor liver transplantation with special reference to ABO-incompatible grafts and small-for-size grafts. World J Surg 2004, 28(1):2-7.
20. Rerolle J.P., Akposso K., Lerolle N., Mougenot B., Ponnelle T., Rondeau E., et al. Tacrolimus-induced hemolytic uremic syndrome and end-stage renal failure after liver transplantation. Clin Transplant 2000, 14(3):262-265.
21. Ramasubbu K., Mullick T., Koo A., Hussein M., Henderson J.M., Mullen K.D., et al. Thrombotic microangiopathy and cytomegalovirus in liver transplant recipients: a case-based review. Transpl Infect Dis 2003, 5(2):98-103.
22. Piscitelli D., Fiore M.G., Rossi R., Casiello M., Sanguedolce F. Unusual case report of thrombotic microangiopathy of the small bowel following liver transplantation, a possible immunosuppressant-induced disease with histological and ultrastructural findings. Sci World J 2009, 9:1031-1034.
23. Nwaba A., MacQuillan G., Adams L.A., Garas G., Delriviere L., Augustson B., et al. Tacrolimus-induced thrombotic microangiopathy in orthotopic liver transplant patients: case series of four patients. Intern Med J 2013, 43(3):328-333.
24. Nishi H., Hanafusa N., Kondo Y., Nangaku M., Sugawara E., Makuuchi M., et al. Clinical outcome of thrombotic microangiopathy after living-donor liver transplantation treated with plasma exchange therapy. Clin J Am Soc Nephrol 2006, 1(4):811-819.
25. Nakazawa Y., Hashikura Y., Urata K., Ikegami T., Terada M., Yagi H., et al. Von Willebrand factor-cleaving protease activity in thrombotic microangiopathy after living donor liver transplantation: a case report. Liver Transpl 2003, 9(12):1328-1333.
26. Matsusaki T., Morimatsu H., Sato T., Sato K., Mizobuchi S., Morita K. Thrombotic microangiopathy after living-donor liver re-transplantation. J Anesth 2010, 24(4):614-617.
27. Mach-Pascual S., Samii K., Beris P. Microangiopathic hemolytic anemia complicating FK506 (Tacrolimus) therapy. Am J Hematol 1996, 52(4):310-312.
28. Luo Y., Zhang A., Huang H., Zheng S. Haemolytic uraemic syndrome after living-donor liver transplantation: is small-for-size graft a potential risk factor?. J Int Med Res 2008, 36(3):599-604.
29. Lo C.M., Liu C.L., Lau G.K., Chan S.C., Ng I.O., Fan S.T. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 2005, 11(7):807-813.
30. Lee C.H., Chen C.L., Lin C.C., Yang C.H., Cheng Y.F., Wang M.C., et al. Plasma exchange therapy for thrombotic thrombocytopenic purpura in pediatric patients with liver transplantation. Trans Proc 2008, 40(8):2554-2556.
31. Saland J.M., Ruggenenti P., Remuzzi G. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol 2009, 20(5):940-949.
32. Hori T., Kaido T., Oike F., Ogura Y., Ogawa K., Yonekawa Y., et al. Thrombotic microangiopathy-like disorder after living-donor liver transplantation: a single-center experience in Japan. World J Gastroenterol 2011, 17(14):1848-1857.
33. Czubkowski P., Pawłowska J., Jankowska I., Teisseyre M., Kaminska D., Marciewicz M., et al. Successful sirolimus rescue in tacrolimus-induced thrombotic microangiopathy after living-related liver transplantation. Pediatr Transplant 2012, 16(6):261-264.
34. Akamatsu N., Sugawara Y., Tamura S., Togashi J., Kaneko J., Makuuchi M. Late mortality from thrombotic microangiopathy after liver transplantation: report of a case. Surg Today 2007, 37(4):345-348.
35. Sekido H., Matsuo K.I., Takeda K., Morioka D., Kubota T., Tanaka K., et al. Successful adult ABO-incompatible liver transplantation: therapeutic strategy for thrombotic microangiopathy is the key to success. Transplantation 2003, 75(9):1605-1607.
36. Furmanczyk A., Komuda-Leszek E., Durlik M. Atypical calcineurin inhibitor-induced haemolytic uremic syndrome after liver transplantation. Ann Transpl 2009, 14(4):47-51.
37. Valbonesi M., Valente U., Pellicci R., Piri C., Ferrari M., Frisoni R., et al. Thrombotic microangiopathy of the miscellaneous secondary type responding to plasma exchange in a liver transplant recipient. Int J Artif Organs 1988, 11(2):131-133.
38. Bonser R.S., Adu D., Franklin I., McMaster P. Cyclosporin-induced haemolytic uraemic syndrome in liver allograft recipient. Lancet 1984, 12(2):1337.
39. McCauley J., Bronsther O., Fung J., Todo S., Starzl T.E. Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet 1989, 12(2):8678-8679.
40. Dzik W.H., Georgi B.A., Khettry U., Jenkins R. Cyclosporin-associated thrombotic thrombocytopenic purpura following liver transplantation - successful treatment with plasma exchange. Transplantation 1987, 44(4):570-572.
41. Yamazaki S., Takayama T., Inoue K., Higaki T., Makuuchi M. Transplantation-related thrombotic microangiopathy triggered by preemptive therapy for hepatitis C virus infection. Transplantation 2008, 86(7):1010-1011.
42. Matsuda D., Toshima T., Ikegami T., Harimoto N., Yamashita Y.I., Yoshizumi T., et al. Thrombotic microangiopathy caused by severe graft dysfunction after living donor liver transplantation: report of a case. Clin J Gastroenterol 2014, 7(2):159-163.
43. Kobayashi T., Wada H., Usui M., Sakurai H., Matsumoto T., Nobori T., et al. Decreased ADAMTS13 levels in patients after living donor liver transplantation. Thromb Res 2009, 124(5):541-545.
44. Nobuoka Y., Wada H., Mizuno S., Kishiwada M., Usui M., Sakurai H., et al. Prolonged thrombocytopenia after living donor liver transplantation is a strong prognostic predictor irrespective of history of splenectomy: the significance of ADAMTS13 and graft function. Int J Hematol 2014, 99(4):418-428.
45. Ko S., Okano E., Kanehiro H., Matsumoto M., Ishizashi H., Uemura M., et al. Plasma ADAMTS13 activity may predict early adverse events in living donor liver transplantation: observations in 3 cases. Liver Transpl 2006, 2(12):859-869.
46. Pereboom I.T., Adelmeijer J., van Leeuwen Y., Hendriks H.G., Porte R.J., Lisman T. Development of a severe von Willebrand factor/ADAMTS13 dysbalance during orthotopic liver transplantation. Am J Transplant 2009, 9(5):1189-1196.
47. Shitrit D., Starobin D., Aravot D., Fink G., Izbicki G., Kramer M. Tacrolimus-induced hemolytic uremic syndrome case presentation in a lung transplant recipient. Transplant Proc 2003, 35(2):627-628.
48. Roberts P., Follette D., Allen R., Katznelson S., Albertson T. Cyclosporine A-associated thrombotic thrombocytopenic purpura following lung transplantation. Transplant Proc 1998, 30(4):1512-1513.
49. Parissis H., Gould K., Dark J. Dangerous drug interactions leading to hemolytic uremic syndrome following lung transplantation. J Cardiothorac Surg 2010, 5(1):70.
50. Myers J.N., Shabshab S.F., Burton N.A., Nathan S.D. Successful use of cyclosporine in a lung transplant recipient with tacrolimus-associated hemolytic uremic syndrome. J Heart Lung Transplant 1999, 18(10):1024-1026.
51. Mal H., Veyradier A., Brugière O., Da Silva D., Colombat M., Azoulay E., et al. Thrombotic microangiopathy with acquired deficiency in ADAMTS 13 activity in lung transplant recipients. Transplantation 2006, 81(12):1628-1632.
52. Butkus D.E., Herrera G.A., Raju S.S. Successful renal transplantation after cyclosporine-associated hemolytic-uremic syndrome following bilateral lung transplantation. Transplantation 1992, 54(1):159-162.
53. Go O., Naqvi A., Tan A., Amzuta I., Lenox R. The spectrum of thrombotic thrombocytopenic purpura: a clinicopathologic demonstration of tacrolimus-induced thrombotic thrombocytopenic purpura in a lung transplant patient. South Med J 2008, 101(7):744-747.
54. Boyer N.L., Niven A., Edelman J. Tacrolimus-associated thrombotic microangiopathy in a lung transplant recipient. BMJ Case Rep 2013, 10.1136/bcr-2012-007351.
55. Scheed A., Jaksch P., Klepetko W. Thrombotic microangiopathy after lung transplantation. J Heart Lung Transplant 2014, 33(4):186.
56. Panchabhai T., Beauclair A., Akindipe O., Budev M.M. Thrombotic micro-angiopathy associated with sirolimus - de'fragmenting' the story. Am J Respir Crit Care Med 2014, 10.1164/ajrccm-conference.2014.189.1_MeetingAbstracts.A1582.
57. Lovric S., Lukasz A., Hafer C., Kielstein J., Haubitz M., Haller H., et al. Removal of elevated circulating angiopoietin-2 by plasma exchange - a pilot study in critically ill patients with thrombotic microangiopathy and anti-glomerular basement membrane disease. Thromb Haemost 2010, 104(5):1038-1043.
58. Galli F.C., Damon L.E., Tomlanovich J., Keith F., Chatterjee K., DeMarco T. Cyclosporine-induced hemolytic uremic syndrome in a heart transplant recipient. J Heart Lung Transplant 1993, 12(3):440-444.
59. Walder B., Ricou B., Suter P.M. Tacrolimus (FK 506)-induced hemolytic uremic syndrome after heart transplantation. J Heart Lung Transplant 1998, 17(10):1004-1006.
60. Mercadal L., Petitclerc T., Assogba U., Beaufils H., Deray G. Hemolytic and uremic syndrome after heart transplantation. Am J Nephrol 2000, 20(5):418-420.
61. Pirenne J. Intestinal failure: autologous reconstruction, intestinal transplantation and intestinal ischemia reperfusion injury. Curr Opin Organ Transplant 2013, 18(3):285.
62. Banerjee D., Kupin W., Roth D. Hemolytic uremic syndrome after multivisceral transplantation treated with intravenous immunoglobulin. J Nephrol 2002, 16(5):733-735.
63. Dierickx D., Monbaliu D., De Rycke A., Wisanto E., Lerut E., Devos T., et al. Thrombotic microangiopathy following intestinal transplantation: a single center experience. Transplant Proc 2010, 42(1):79-81.
64. Humar A., Jessurun J., Sharp H.L., Gruessner R.W. Hemolytic uremic syndrome in small-bowel transplant recipients: the first two case reports. Transpl Int 1999, 12(5):387-390.
65. Paramesh A.S., Grosskreutz C., Florman S.S., Gondolesi G., Sharma S., Kaufman S., et al. Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation. Transplantation 2004, 77(1):129-131.
66. Caires R.A., Marques I.D.B., Repizo L.P., Sato V.A.H., Carmo L.P.F., Machado D.J.B., et al. De novo thrombotic microangiopathy after kidney transplantation: clinical features, treatment and long-term patient and graft survival. Transplantation Proceedings 2012, 44:2388-2390.
67. Altschule M.D. A rare type of acute thrombocytopenic purpura: widespread formation of platelet thrombi in capillaries. N Engl J Med 1942, 227(13):477-479.
68. Goldberg R.J., Nakagawa T., Johnson R.J., Thurman J.M. The role of endothelial cell injury in thrombotic microangiopathy. Am J Kidney Dis 2010, 56(6):1168-1174.
69. Bombeli T., Schwartz B.R., Harlan J.M. Endothelial cells undergoing apoptosis become proadhesive for nonactivated platelets. Blood 1999, 93(11):3831-3838.
70. Cailhier J.F., Nolin L., Hébert M.J. Thrombotic microangiopathy following renal ischaemia and revascularization: apoptosis of endothelial cells in action. Nephrol Dial Transplant 2001, 16(8):1725-1726.
71. Land W.G. Emerging role of innate immunity in organ transplantation: part I: evolution of innate immunity and oxidative allograft injury. Transplant Rev (Orlando) 2012, 26(2):60-72.
72. Land W., Schneeberger H., Schleibner S. The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation 1994, 57(2):211-217.
73. Matzinger P. The evolution of the danger theory. Expert Rev Clin Immunol 2012, 8(4):311-317.
74. Wiener Y., Nakhleh R.E., Lee M.W., Escobar F.S., Venkat K.K., Kupin W.L., et al. Prognostic factors and early resumption of cyclosporin A in renal allograft recipients with thrombotic microangiopathy and hemolytic uremic syndrome. Clin Transplant 1997, 11(3):157-162.
75. Bernardo A., Ball C., Nolasco L., Moake J.F., Dong J. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004, 104(1):100-106.
76. Reynolds J.C., Agodoa L.Y., Yuan C.M., Abbott K.C. Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis 2003, 42(5):1058-1068.
77. Noris M., Remuzzi G. Thrombotic microangiopathy after kidney transplantation. Am J Transplant 2010, 10(7):1517-1523.
78. Lovric S., Kielstein J.T., Kayser D., Bröcker V., Becker J., Hiss M., et al. Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients - a case series. Nephrol Dial Transplant 2011, 26(9):3032-3038.
79. Saikali J.A., Truong L.D., Suki W.N. Sirolimus may promote thrombotic microangiopathy. Am J Transplant 2003, 3:229-230.
80. Crew R.J., Radhakrishnan J., Cohen D.J., Stern L., Goldstein M., Hardy M., et al. De novo thrombotic microangiopathy following treatment with sirolimus: report of two cases. Nephrol Dial Transplant 2005, 20(1):203-209.
81. Eremina V., Jefferson J.A., Kowalewska J., Hochster H., Haas M., Weisstuch J., et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008, 358(11):1129-1136.
82. Ramzy D., Rao V., Tumiati L.C., Xu N., Miriuka S., Delgado D., et al. Role of endothelin-1 and nitric oxide bioavailability in transplant-related vascular injury: comparative effects of rapamycin and cyclosporine. Circulation 2006, 114(1):214-219.
83. Pham P.-T.T., Danovitch G.M., Wilkinson A.H., Gritsch H., Pham P.-C.T., Eric T., et al. Inhibitors of ADAMTS13: a potential factor in the cause of thrombotic microangiopathy in a renal allograft recipient. Transplantation 2002, 74(8):1077-1080.
84. Uemura M., Fujimura Y., Ko S., Matsumoto M., Nakajima Y., Fukui H. Pivotal role of ADAMTS13 function in liver diseases. Int J Hematol 2010, 91(1):20-29.
85. Karthikeyan V., Parasuraman R., Shah V., Vera E., Venkat K.K. Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation. Am J Transplant 2003, 3(10):1289-1294.
86. Choi C.M., Schmaier A.H., Snell M.R., Lazarus H.M. Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment. Drugs 2009, 69(2):183-198.
87. George J.N., Al-Nouri Z.L. Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes. ASH Education Program book 2012, 1:604-609.
88. Schwartz J., Winters J.L., Padmanabhan A., Balogun R., Delaney M., Linenberger M., et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American Society for Apheresis: The Sixth Special Issue 2013, 284(7):145-284.
89. Mizuno S., Wada H., Hamada T., Nobuoka Y., Tabata M., Nobori T., et al. Lethal hepatic infarction following plasma exchange in living donor liver transplant patients. Transpl Int 2011, 24(7):57-58.
90. Swisher K.K., Terrell D.R., Vesely S.K., Kremer Hovinga J.A., Lämmle B., George J.N. Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion 2009, 49(5):873-887.
91. Wolff D., Wilhelm S., Hahn J., Gentilini C., Hilgendorf I., Steiner B., et al. Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease. Bone Marrow Transplant 2006, 38(6):445-451.
92. Togashi J., Sugawara Y., Akamatsu N., Tamura S., Tanaka T., Kaneko J., et al. A single-center experience of the use of interleukin-2 receptor antagonists for various situations in liver transplant recipients. Transplant Proc 2014, 46(3):739-743.
93. Wilson C.H., Brown A.L., White S.A., Goodship T.H.J., Sheerin N.S., Manas D.M. Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab. Transplantation 2011, 92(8):42-43.
94. Mörtzell M., Berlin G., Nilsson T., Axelsson E.G., Efvergren M., Audzijoni J., et al. Thrombotic microangiopathy. Transfus Apher Sci 2011, 45(2):119-123.
95. Ashman N., Chapagain A., Dobbie H., Raftery M.J., Sheaff M.T., Yaqoob M.M. Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy. Am J Transplant 2009, 9(2):424-427.